Heptares Therapeutics Acquired by Sosei for up to $400m


In February 2015, Sosei acquired 100% of Heptares’ share capital for $180 million in cash consideration and up to $220 million contingent upon the successful progression of the company’s pipeline and platform.

Heptares Therapeutics Limited

Heptares Therapeutics Limited
GPCR drug discovery & development

Downloads

DownloadPress Release